Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-Alpha and Thalidomide in Relapsed/Refractory Low-Grade Follicular Lymphoma
NCT00015912Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2001
- Primary completion
- Sep 2003
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide and interferon alfa in follicular lymphoma (FL), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 2 years. Started Jul 2001; status: terminated.
02
Drugs
thalidomideinterferon alfa
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00015912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00015912.